A vial of the Moderna's COVID-19 vaccine, Bivalent. Though the shots are free to pretty much anyone who wants one in the U.S. as long as federal stockpiles hold out, the next update of the vaccine might be costly for some people who lack health insurance. RINGO CHIU/AFP via Getty Images hide caption
A bottle of Johnson & Johnson baby powder is displayed on a table. J&J pulled its iconic Johnson's baby powder off the shelves in the U.S. in 2020. Justin Sullivan/Getty Images hide caption
An arrangement of pills of the opioid oxycodone-acetaminophen in New York. Idaho officials on Friday agreed to a $119 million settlement with drugmaker Johnson & Johnson and three major distributors over their role in the opioid addiction crisis. Patrick Sison/AP hide caption
Hope Schiller Wilt (left) and her daughter, Hanna Wilt, outside her home on Nov. 19, 2021, in Manasquan, N.J. The family plans to continue her lawsuit. "It's what she wanted," her mother said. Jackie Molloy for NPR hide caption
Johnson & Johnson's baby powder is displayed on a table in this photo illustration. A federal judge has allowed Johnson & Johnson's spinoff of a unit to proceed with a controversial bankruptcy. Justin Sullivan/Getty Images hide caption
Nurse Sandra Lindsay celebrates after receiving her COVID-19 Pfizer vaccine booster at Long Island Jewish Medical Center in New York in October. Lindsay was the first person known to receive a COVID vaccine in the United States vaccination campaign — on Dec. 14, 2020. Her vaccination card is displayed at the COVID-19 exhibit in the Smithsonian Museum of American History. Lev Radin/Pacific Press via Getty Images hide caption
Ari Blank got a comforting hand-squeeze from his mom in May as he was vaccinated against COVID-19 in Bloomfield Hills, Mich. This week, the Food and Drug Administration authorized the use of Pfizer's vaccine in even younger kids — ages 5 to 11. Jeff Kowalsky/AFP via Getty Images hide caption
A health care worker administers a Pfizer-BioNTech COVID-19 vaccine Thursday at Life of Hope Center in New York City. Michael M. Santiago/Getty Images hide caption
In this photo illustration, a container of Johnson's baby powder sits on a table in 2019. Justin Sullivan/Getty Images hide caption
Johnson & Johnson has asked U.S. regulators to allow booster shots of its COVID-19 vaccine. David Zalubowski/AP hide caption
The COVID-19 vaccine from Johnson & Johnson was a one-shot regime. But data shows that people who got the shot may have waning immunity, and some doctors say a second shot would be a good idea. Stephen Zenner/Getty Images hide caption
Johnson & Johnson shared data from the Phase 3 trial of its booster shot on Tuesday indicating a booster shot at six months provided a 12-fold increase in antibodies. Eva Marie Uzctegui/Bloomberg via Getty Images hide caption
A nurse fills a syringe with Johnson & Johnson's COVID-19 vaccine at a clinic in Pasadena, Calif., on Thursday. Robyn Beck/AFP via Getty Images hide caption
Johnson & Johnson is facing tens of thousands of lawsuits over claims that its talcum-based products caused users to develop cancer. The company says its powder products are safe. Frederic J. Brown/AFP via Getty Images hide caption
The New York attorney general says Johnson & Johnson has agreed to pay $230 million to settle claims that the it helped fuel the opioid crisis. Steven Senne/AP hide caption
Rep. Mariannette Miller-Meeks, R-Iowa, listens as Robert Kramer, president and chief executive officer of Emergent BioSolutions, testifies during a Wednesday hearing of the House Select Subcommittee on the Coronavirus Crisis. Pool/Getty Images hide caption
The Emergent BioSolutions Bayview Campus plant in Baltimore has stopped producing vaccine material following an FDA inspection that found numerous problems. The plant was slated to become part of the Johnson & Johnson COVID-19 vaccine production process. Tasos Katopodis/Getty Images hide caption
Government health officials are recommending a "pause" in vaccinations with the Johnson & Johnson COVID-19 vaccine. Stephen Zenner/Getty Images hide caption
A medical worker at South Shore University Hospital gets ready to administer the newly available Johnson & Johnson COVID-19 vaccine in Bay Shore, N.Y., Wednesday. Clinical research found it to be 85% effective in preventing severe disease four weeks after vaccination, and it has demonstrated promising indications of protection against a couple of concerning variants of the coronavirus. Spencer Platt/Getty Images hide caption
A health care worker holds a vial of the Johnson & Johnson COVID-19 vaccine at South Shore University Hospital in Bay Shore, N.Y., on Wednesday. Bloomberg/Bloomberg via Getty Images hide caption
President Biden keeps a note card in his suit pocket with the running tally of how many Americans have died from COVID-19 and how many have been vaccinated. Evan Vucci/AP hide caption
The phase 3 trial of Johnson & Johnson's COVID-19 vaccine candidate has been paused as the company investigates what it says is a study participant's "unexplained illness." Cheryl Gerber/AP hide caption